Bristol-Myers Squibb Company (NYSE:BMY) — Market Cap & Net Worth
Market Cap & Net Worth: Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (NYSE:BMY) has a market capitalization of $114.19 Billion ($114.19 Billion) as of June 18, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #213 globally and #113 in its home market, demonstrating a 0.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bristol-Myers Squibb Company's stock price $55.92 by its total outstanding shares 2042071247 (2.04 Billion). Review Bristol-Myers Squibb Company balance sheet liabilities to assess the company's total debt and financial obligations.
Bristol-Myers Squibb Company Market Cap History: 2015 to 2026
Bristol-Myers Squibb Company's market capitalization history from 2015 to 2026. Data shows growth from $105.98 Billion to $114.19 Billion (1.28% CAGR).
Index Memberships
Bristol-Myers Squibb Company is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.26 Trillion | 3.50% | #8 of 24 |
|
S&P 500 Index
GSPC
|
$62.23 Trillion | 0.23% | #92 of 503 |
|
S&P 100
OEX
|
$44.56 Trillion | 0.33% | #71 of 101 |
Weight: Bristol-Myers Squibb Company's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bristol-Myers Squibb Company Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bristol-Myers Squibb Company's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.29x
Bristol-Myers Squibb Company's market cap is 2.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
15.62x
Bristol-Myers Squibb Company's market cap is 15.62 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $91.68 Billion | $19.43 Billion | $4.46 Billion | 4.72x | 20.57x |
| 2017 | $98.75 Billion | $20.78 Billion | $1.01 Billion | 4.75x | 98.06x |
| 2018 | $86.01 Billion | $22.56 Billion | $4.92 Billion | 3.81x | 17.48x |
| 2019 | $109.87 Billion | $26.14 Billion | $3.44 Billion | 4.20x | 31.95x |
| 2020 | $110.32 Billion | $42.52 Billion | -$8.99 Billion | 2.59x | N/A |
| 2021 | $113.50 Billion | $46.38 Billion | $6.99 Billion | 2.45x | 16.23x |
| 2022 | $135.04 Billion | $46.16 Billion | $6.33 Billion | 2.93x | 21.34x |
| 2023 | $99.74 Billion | $45.01 Billion | $8.03 Billion | 2.22x | 12.43x |
| 2024 | $115.50 Billion | $48.30 Billion | -$8.95 Billion | 2.39x | N/A |
| 2025 | $110.15 Billion | $48.19 Billion | $7.05 Billion | 2.29x | 15.62x |
Competitor Companies of BMY by Market Capitalization
Companies near Bristol-Myers Squibb Company in the global market cap rankings as of June 18, 2026.
Key companies related to Bristol-Myers Squibb Company by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #26 globally with a market cap of $566.62 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1122.50 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #26 | Johnson & Johnson | NYSE:JNJ | $566.62 Billion | $235.18 |
| #42 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $222.47 |
Bristol-Myers Squibb Company Historical Marketcap From 2015 to 2026
Between 2015 and today, Bristol-Myers Squibb Company's market cap moved from $105.98 Billion to $ 114.19 Billion, with a yearly change of 1.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $114.19 Billion | +3.67% |
| 2025 | $110.15 Billion | -4.63% |
| 2024 | $115.50 Billion | +15.81% |
| 2023 | $99.74 Billion | -26.14% |
| 2022 | $135.04 Billion | +18.98% |
| 2021 | $113.50 Billion | +2.88% |
| 2020 | $110.32 Billion | +0.41% |
| 2019 | $109.87 Billion | +27.74% |
| 2018 | $86.01 Billion | -12.90% |
| 2017 | $98.75 Billion | +7.71% |
| 2016 | $91.68 Billion | -13.49% |
| 2015 | $105.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Bristol-Myers Squibb Company was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $114.19 Billion USD |
| MoneyControl | $114.19 Billion USD |
| MarketWatch | $114.19 Billion USD |
| marketcap.company | $114.19 Billion USD |
| Reuters | $114.19 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for… Read more